ANI Pharmaceuticals Inc.

31.95+0.1500+0.47%Vol 84.37K1Y Perf 17.27%
Sep 24th, 2021 16:00 DELAYED
BID31.94 ASK32.00
Open31.36 Previous Close31.80
Pre-Market- After-Market-
 - -  - -%
Target Price
45.00 
Analyst Rating
Moderate Buy 2.00
Potential %
40.85 
Finscreener Ranking
★★★+     50.97
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★     51.89
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★+     42.40
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
51.06 
Earnings Rating
Strong Sell
Market Cap407.75M 
Earnings Date
4th Nov 2021
Alpha-0.02 Standard Deviation0.12
Beta1.26 

Today's Price Range

30.7132.17

52W Range

23.5540.00

5 Year PE Ratio Range

-410.20213.40

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
10.59%
1 Month
13.82%
3 Months
-3.30%
6 Months
1.72%
1 Year
17.27%
3 Years
-40.08%
5 Years
-52.06%
10 Years
-63.78%

TickerPriceChg.Chg.%
ANIP31.950.15000.47
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Financial StrengthValueIndustryS&P 500US Markets
1.30
2.10
0.50
1.07
-1.00
Leverage Ratio 2.40
ProfitabilityValueIndustryS&P 500US Markets
59.30
-4.80
16.00
3.00
-7.90
RevenueValueIndustryS&P 500US Markets
213.38M
16.73
2.60
13.57
Earnings HistoryEstimateReportedSurprise %
Q02 20210.510.49-3.92
Q01 20210.580.9258.62
Q04 20200.850.65-23.53
Q03 20200.780.813.85
Q02 20200.570.55-3.51
Q01 20200.760.8917.11
Q04 20191.020.93-8.82
Q03 20191.321.07-18.94
Earnings Per EndEstimateRevision %Trend
9/2021 QR0.55-21.43Negative
12/2021 QR0.833.75Positive
12/2021 FY2.771.84Positive
12/2022 FY3.17-12.43Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report0.55
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume84.37K
Shares Outstanding12.76M
Shares Float8.30M
Trades Count1.68K
Dollar Volume1.97M
Avg. Volume58.74K
Avg. Weekly Volume49.36K
Avg. Monthly Volume63.43K
Avg. Quarterly Volume61.31K

ANI Pharmaceuticals Inc. (NASDAQ: ANIP) stock closed at 31.95 per share at the end of the most recent trading day (a 0.47% change compared to the prior day closing price) with a volume of 87.98K shares and market capitalization of 407.75M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 338 people. ANI Pharmaceuticals Inc. CEO is Nikhil Lalwani.

The one-year performance of ANI Pharmaceuticals Inc. stock is 17.27%, while year-to-date (YTD) performance is 10.02%. ANIP stock has a five-year performance of -52.06%. Its 52-week range is between 23.55 and 40, which gives ANIP stock a 52-week price range ratio of 51.06%

ANI Pharmaceuticals Inc. currently has a PE ratio of -20.30, a price-to-book (PB) ratio of 1.92, a price-to-sale (PS) ratio of 1.75, a price to cashflow ratio of 25.60, a PEG ratio of 2.32, a ROA of -3.55%, a ROC of -2.25% and a ROE of -8.75%. The company’s profit margin is -7.90%, its EBITDA margin is 16.00%, and its revenue ttm is $213.38 Million , which makes it $16.73 revenue per share.

Of the last four earnings reports from ANI Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.55 for the next earnings report. ANI Pharmaceuticals Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for ANI Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $45, which is +40.85% compared to the current price. The earnings rating for ANI Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ANI Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ANI Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.66, ATR14 : 1.38, CCI20 : 150.74, Chaikin Money Flow : 0.26, MACD : 0.20, Money Flow Index : 78.99, ROC : 13.30, RSI : 63.07, STOCH (14,3) : 96.07, STOCH RSI : 1.00, UO : 68.34, Williams %R : -3.93), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ANI Pharmaceuticals Inc. in the last 12-months were: Patrick D. Walsh (Buy at a value of $261 355)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
2 (66.67 %)
Moderate Buy
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Hold
1 (33.33 %)
1 (33.33 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Strong Buy
1.33

ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures and markets generic prescription pharmaceuticals, made in the U.S.A. It manufactures liquid, powder and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone, and Vancomycin.

CEO: Nikhil Lalwani

Telephone: +1 218 634-3500

Address: 210 Main Street West, Baudette 56623, MN, US

Number of employees: 338

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

55%45%

News

Stocktwits